01 February 2004
G-CSF in solid tumor chemotherapy: a tailored regimen reduces febrile neutropenia, treatment delays and direct costsNicolas Tsavaris, Christos Kosmas, Panagiotis Gouveris, Maria Vadiak, Antonis Dimitrakopoulos, Dimitra Karadima, Efterpi Pagouni, George Panagiotakopoulos, Evanthia Tzima, Sevasti Ispoglou, Dimitris Sakelariou, Christos Koufos
Med Sci Monit 2004; 10(2): PI24-28 :: ID: 11583
Background:Current guidelines do not recommend G-CSF for patients with risk factors for neutropenia.Material/Methods: One-hundred patients undergoing chemotherapy were randomized to treatment with G-CSF at 5 Kg/kg for established febrile neutropenia (ANC <1000/micro l) (Group A) or G-CSF at 263 Kg/day if ANC was 1500/micro l or less on the day of the expected nadir, with the duration of treatment determined by the severity of neutropenia (Group B).
Results: The number of doses of G-CSF was similar in the two groups. There were 34 cases of febrile neutropenia in Group A, but none in Group B (p=0.0001). Hospital admission for febrile neutropenia, antibiotic use and delays in chemotherapy were all significantly more common in Group A. Total direct costs were estimated to be € 66, 646 for Group A and € 47, 119 for Group B.
Conclusions: Tailoring treatment does not increase G-CSF use, but significantly reduces febrile neutropenia and treatment delays and lowers direct costs.
Keywords: Adult, Antineoplastic Combined Chemotherapy Protocols - administration & dosage, Antineoplastic Combined Chemotherapy Protocols - economics, Drug Administration Schedule, Fever - blood, Fever - complications, Fever - drug therapy, Granulocyte Colony-Stimulating Factor - administration & dosage, Granulocyte Colony-Stimulating Factor - economics, Leukocyte Count, Neoplasms - blood, Neoplasms - complications, Neoplasms - drug therapy, Neutropenia - blood, Neutropenia - complications, Neutropenia - drug therapy, Neutrophils - cytology, Neutrophils - drug effects, Adult, Antineoplastic Combined Chemotherapy Protocols - economics, Drug Administration Schedule, Fever - drug therapy, Granulocyte Colony-Stimulating Factor - economics, Leukocyte Count, Neoplasms - drug therapy, Neutropenia - drug therapy, Neutrophils - drug effects
This Week Editorial
20 September 2021 : EditorialEditorial: Autoantibodies to Components of the Immune System, Including Type 1 Interferons, and the Risk of Severe COVID-19
Med Sci Monit 2021; 27:e934766
22 September 2021 : EditorialEditorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic M...
Med Sci Monit In Press; DOI: 10.12659/MSM.934854
08 September 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit In Press; DOI: 10.12659/MSM.932788
16 July 2021 : Review articleSilent Hypoxemia in Patients with COVID-19 Pneumonia: A Review
Med Sci Monit In Press; DOI: 10.12659/MSM.930776
24 Sep 2021 : Clinical ResearchA Single-Center Study of a Resin Inlay Dental Implant-Fixed Prosthesis for Closing Proximal Contact Loss in...
Med Sci Monit In Press; DOI: 10.12659/MSM.933809
24 Sep 2021 : Database AnalysisRelationships Between Obstructive Sleep Apnea and Cardiovascular Disease: A Bibliometric Analysis (2010-2021)
Med Sci Monit In Press; DOI: 10.12659/MSM.933448
24 Sep 2021 : Database AnalysisA Statistical Prediction Model for Survival After Kidney Transplantation from Deceased Donors
Med Sci Monit In Press; DOI: 10.12659/MSM.933559
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700